Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Repligen Corporation stock

Learn how to easily invest in Repligen Corporation stock.

Repligen Corporation is a medical instruments & supplies business based in the US. Repligen Corporation shares (RGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Repligen Corporation employs 1,128 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Repligen Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RGEN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Repligen Corporation stock price (NASDAQ: RGEN)

Use our graph to track the performance of RGEN stocks over time.

Repligen Corporation shares at a glance

Information last updated 2022-01-18.
Latest market close$188.46
52-week range$162.29 - $327.32
50-day moving average $256.58
200-day moving average $239.15
Wall St. target price$312.56
PE ratio 91.9848
Dividend yield N/A (0%)
Earnings per share (TTM) $2.10

Buy Repligen Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Stocks
$0
0%
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$0
$1 per month
$5
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Public
Stocks, ETFs, Cryptocurrency
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Repligen Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Repligen Corporation price performance over time

Historical closes compared with the close of $188.46 from 2022-01-20

1 week (2022-01-14) -2.48%
1 month (2021-12-21) -29.57%
3 months (2021-10-21) -30.40%
6 months (2021-07-21) -7.44%
1 year (2021-01-21) -13.12%
2 years (2020-01-21) 86.58%
3 years (2019-01-18) 223.09%
5 years (2017-01-20) 517.50%

Is Repligen Corporation stock undervalued or overvalued?

Valuing Repligen Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Repligen Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Repligen Corporation's P/E ratio

Repligen Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 92x. In other words, Repligen Corporation shares trade at around 92x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Repligen Corporation's PEG ratio

Repligen Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.59. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Repligen Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Repligen Corporation's EBITDA

Repligen Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $190.4 million.

The EBITDA is a measure of a Repligen Corporation's overall financial performance and is widely used to measure a its profitability.

Repligen Corporation financials

Revenue TTM $592.7 million
Operating margin TTM 26.24%
Gross profit TTM $210.4 million
Return on assets TTM 5.23%
Return on equity TTM 8.37%
Profit margin 20.06%
Book value $31.03
Market capitalisation $10.7 billion

TTM: trailing 12 months

Repligen Corporation share dividends

We're not expecting Repligen Corporation to pay a dividend over the next 12 months.

Repligen Corporation share price volatility

Over the last 12 months, Repligen Corporation's shares have ranged in value from as little as $162.29 up to $327.32. A popular way to gauge a stock's volatility is its "beta".

RGEN.US volatility(beta: 0.77)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Repligen Corporation's is 0.7745. This would suggest that Repligen Corporation's shares are less volatile than average (for this exchange).

Repligen Corporation overview

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations.

Frequently asked questions

What percentage of Repligen Corporation is owned by insiders or institutions?
Currently 6.824% of Repligen Corporation shares are held by insiders and 86.623% by institutions.
How many people work for Repligen Corporation?
Latest data suggests 1,128 work at Repligen Corporation.
When does the fiscal year end for Repligen Corporation?
Repligen Corporation's fiscal year ends in December.
Where is Repligen Corporation based?
Repligen Corporation's address is: Building 1, Waltham, MA, United States, 02453
What is Repligen Corporation's ISIN number?
Repligen Corporation's international securities identification number is: US7599161095
What is Repligen Corporation's CUSIP number?
Repligen Corporation's Committee on Uniform Securities Identification Procedures number is: 759916109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site